SWOG clinical trial number
SWOG-9457
Paclitaxel (Taxol®) and Carboplatin for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II
Closed
Phase
Accrual
86%
Published
Abbreviated Title
Advanced Bladder
Activated
07/15/1996
Closed
04/15/2000
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2005
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study
2003
Southwest Oncology Group studies in bladder cancer
2000
A Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: The importance of survival as a clinical trial endpoint
1999
Carboplatin and paclitaxel (CARBO/TAX) for advanced transitional cell carcinoma (TCC) of the urothelium.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase